SMTL ID : 4dff.1 (1 other biounit)

The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.11 Å

Oligo State

monomer

Ligands

1 x MG: MAGNESIUM ION(Non-covalent)

MG.1: 5 residues within 4Å: Chain A: H.126, D.127, H.130, H.158 Ligands: ZN.2 5 PLIP interactions: 5 Ligand-Water interactions Metal complexes: H2O.1, H2O.1, H2O.1, H2O.1, H2O.2

1 x ZN: ZINC ION(Non-covalent)

ZN.2: 7 residues within 4Å: Chain A: H.88, H.92, V.96, H.126, D.127, D.237 Ligands: MG.1 5 PLIP interactions: 4 interactions with chain A, 1 Ligand-Water interactions Metal complexes: A:H.92, A:H.126, A:D.127, A:D.237, H2O.1

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Ho, G.D. et al., The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg.Med.Chem.Lett. (2012)

Release Date

2012-03-14

Peptides

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A

Related Entries With Identical Sequence